M&A activity in life sciences has surged, driven by investor activism and the need for innovation, with 2023 deals valued at $163bn, up from $135bn in 2022. Companies are focusing on strategic partnerships, divestments of non-core assets, and leveraging AI/GenAI for enhanced deal-making efficiency. As pharma faces a significant 'patent cliff,' the emphasis on acquiring innovative assets is critical for sustaining growth and competitiveness.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.